The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Is incomplete estradiol suppression during aromatase inhibitor treatment in post-menopausal patients with breast cancer due to insufficient systemic drug concentrations?
 
Daniel Louis Hertz
No Relationships to Disclose
 
Kelley M. Kidwell
No Relationships to Disclose
 
Kelly A Speth
No Relationships to Disclose
 
Christina L Gersch
No Relationships to Disclose
 
Zeruesenay Desta
No Relationships to Disclose
 
Anna Maria Storniolo
No Relationships to Disclose
 
Vered Stearns
Research Funding - Abbvie; Celgene; MedImmune; Merck; Novartis; Pfizer; Puma Biotechnology
 
Todd C Skaar
No Relationships to Disclose
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Honoraria - Lilly
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Travel, Accommodations, Expenses - Janssen Diagnostics
 
Norah Lynn Henry
Research Funding - BioMarin; Celldex
 
James M. Rae
No Relationships to Disclose